SETD1A

1. SETD1A impairs cognitive function in humans.

   “accompanied by allele dose-dependent cognitive deficits in adulthood.”

   Humanshomozygous carriers

   Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant

   Research square·13 Jul 2026Preprint

1. SETD1A inhibits cellular senescence in human cells.

   “SETD1A knockdown accelerated NPCs senescence and aggravated IDD”

   Cellsknockdownnucleus pulposus

   SETD1A Regulates Glycolysis and Senescence of Nucleus Pulposus Cells via H3K4me3-HELZ2/PPARα-HIF1α Axis to Drive Intervertebral Disc Degeneration

   Advanced science (Weinheim, Baden-Wurttemberg, Germany)·31 Mar 2026

More on Cellular senescence

1. SETD1A prevents intervertebral disc degeneration in humans.

   “SETD1A knockdown accelerated NPCs senescence and aggravated IDD”

   Animalsknockdownnucleus pulposus

   SETD1A Regulates Glycolysis and Senescence of Nucleus Pulposus Cells via H3K4me3-HELZ2/PPARα-HIF1α Axis to Drive Intervertebral Disc Degeneration

   Advanced science (Weinheim, Baden-Wurttemberg, Germany)·31 Mar 2026

More on Intervertebral disc degeneration

1. SETD1A raises the risk of bipolar disorder in humans (nearly two-fold).

   “Psychiatric and cognitive phenotyping revealed nearly two-fold increased risk for bipolar disorder, accompanied by allele dose-dependent cognitive deficits in adulthood.”

   Humanshomozygous carriers

   Clinical, cellular, and genomic consequences of a population-enriched SETD1A missense variant

   Research square·13 Jul 2026Preprint

More on Bipolar disorder